目的：探讨肺力咳合剂辅助布地奈德福莫特罗粉吸入剂治疗咳嗽变异性哮´（CVA）的临床疗效及对气道炎症的影响。方法：纳入北京市第一中西医结合医院医院呼吸内科收治的72例CVA患者为研究对象，随机分为采用布地奈德福莫特罗粉吸入剂进行治疗的对照组（36例）和采用布地奈德福莫特罗粉吸入剂+肺力咳合剂进行治疗的实验组（36例），比较两组临床疗效、肺功能、气道炎症及不良反应等情况。结果：实验组总有效率为94.44%，对照组总有效率为77.78%，实验组总有效率显著高于对照组；治疗后两组患者白天、夜间咳嗽症状评分、一秒用力呼气容积（FEV₁）、FEV₁/用力肺活量（FVC）、PEF占比（PEF pred%）及白介素-10（IL-10）水平均明显高于治疗前，两组治疗后嗜酸性粒细胞（EOS）百分比、炎性介质白介素-4（IL-4）及白介素-5（IL-5）水平均显著下降，且实验组变化幅度均明显大于对照组；两组均未见严重不良反应，不良反应发生率无显著差异。结论：采用肺力咳合剂辅助布地奈德福莫特罗粉吸入剂对CVA患者治疗的效果显著，患者咳嗽症状明显缓解，肺功能及气道炎症均得到良好改善，且安全性较高。

Objective To explore the clinical efficacy of Feilike mixture combined with budesonide formoterol powder inhalants in the treatment of cough variant asthma (CVA) and its effect on airway inflammation. Methods A total of 72 patients with CVA enrolled in Respiratory Medicine Beijing First Hospital of Integrated Chinese and Western Medicine were selected for the study and randomly divided into the control group (n=36, treated with budesonide formoterol powder inhalants) and the experimental group (n=36, treated with budesonide formoterol powder inhalants and Feilike mixture). The clinical efficacy, pulmonary function, airway inflammation and adverse reactions were compared between the two groups. Results The total effective rate was 94.44% in the experimental group, which was significantly higher than that in the control group with 77.78%. After treatment, the day or nocturnal cough symptom scores, one-second forced expiratory volume (FEV1), FEV1/forced vital capacity (FVC), the ratio of PEF (PEF pred%) and interleukin-10(IL-10) level were significantly higher than those before treatment, After treatment, the levels of the eosinophil (EOS) percentage, inflammatory mediators interleukin-4(IL-4) and interleukin-5(IL-5) were significantly decreased in the two groups, and the changing degree in the experimental group was significantly higher than that in the control group. There was no significant adverse reaction between the two groups as well as the incidence rate of adverse reactions. Conclusion The use of Feilike mixture combined with budesonide formoterol powder inhalants can have significant effects in the treatment of CVA children, such as relieving the cough symptoms of children and improving lung function and airway inflammation with high safety.